二甲双胍对结直肠癌异种移植瘤缺氧及放疗疗效的影响:[18F]HX4 PET显像研究
在Colo205结直肠癌异种移植小鼠模型中,静脉给予100 mg/kg二甲双胍可降低肿瘤对[18F]HX4的摄取(TBR从2.53±0.30降至2.28±0.26,p=0.04),但未观察到二甲双胍对放疗疗效的附加作用;基线[18F]HX4 TBR是肿瘤倍增时间的负向预后生物标志物(HR=2.39,p=0.02)。
要点
- 二甲双胍可降低Colo205肿瘤[18F]HX4摄取,提示肿瘤缺氧改善。
- 二甲双胍对15 Gy单次放疗的长期疗效无附加作用。
- 基线[18F]HX4 TBR较高与肿瘤倍增时间较短相关(HR=2.39)。
核心结论
- 二甲双胍降低Colo205肿瘤的[18F]HX4摄取,但对放疗疗效无附加效应。
- [18F]HX4有潜力作为预后影像生物标志物。
研究设计与样本
- Colo205结直肠癌异种移植小鼠共40只,基线行[18F]HX4 μPET/CT显像。
- 次日静脉给予100 mg/kg二甲双胍或生理盐水(每组20只),30分钟后再次显像评估肿瘤缺氧变化。
- 两天后分为四组(每组10只):对照、二甲双胍、放疗、联合,给予第二剂二甲双胍或生理盐水后30分钟行15 Gy单次放疗或假照射。
- 每周三次游标卡尺测量肿瘤生长以评估疗效。
主要发现
- 二甲双胍组肿瘤内[18F]HX4 TBR均值从2.53±0.30降至2.28±0.26(p=0.04),生理盐水组从2.56±0.39升至3.08±0.39(p=0.2)。
- 对照组、二甲双胍组、放疗组和联合组的中位肿瘤倍增时间分别为6、8、41和43天(log-rank p<0.0001)。
- 未检测到二甲双胍特异的治疗效应。
- 基线[18F]HX4 TBR是肿瘤倍增时间的负向预后生物标志物(风险比2.39;p=0.02)。
关键数值与推荐
- 二甲双胍剂量100 mg/kg静脉给药,放疗单次15 Gy。
- [18F]HX4 TBR变化:二甲双胍组2.53±0.30至2.28±0.26(p=0.04);生理盐水组2.56±0.39至3.08±0.39(p=0.2)。
- 中位肿瘤倍增时间:对照6天、二甲双胍8天、放疗41天、联合43天(log-rank p<0.0001)。
- 基线[18F]HX4 TBR对肿瘤倍增时间的风险比2.39(p=0.02)。
临床怎么用
- 二甲双胍可能改善肿瘤缺氧,但在此模型中未增强放疗疗效,临床联合需进一步验证。
- [18F]HX4 PET显像或可用于评估肿瘤缺氧及预后分层。
局限性
- 研究为临床前异种移植小鼠模型,结果外推至患者需谨慎。
- 样本量有限(每组10只),可能影响效应检测的统计效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a colorectal cancer xenograft model, we investigated the therapeutic effect of metformin on tumor hypoxia with [18F]flortanidazole ([18F]HX4) small-animal positron emission tomography (μPET). We also assessed the additive effect of metformin on long-term radiotherapy outcome and we studied the potential of [18F]HX4 as a predictive and/or prognostic biomarker within this setup. METHODS: Colo205-bearing mice (n = 40) underwent a baseline [18F]HX4 hypoxia μPET/computed tomography (CT) scan. The next day, mice received 100 mg/kg metformin or saline intravenously (n = 20/group) and [18F]HX4 was administered intravenously 30 min later, whereupon a second μPET/CT scan was performed to assess changes in tumor hypoxia. Two days later, mice were further divided into four therapy groups (n = 10/group): control (1), metformin (2), radiotherapy (3), and metformin + radiotherapy, i.e., combination (4). Then, they received a second dose of metformin (groups 2 and 4) or saline (groups 1 and 3), followed by a single radiotherapy dose of 15 Gy (groups 3 and 4) or sham irradiation (groups 1 and 2) 30 min later. Tumor growth was followed three times a week by caliper measurements to assess the therapeutic outcome. RESULTS: [18F]HX4 uptake decreased in metformin-treated tumors with a mean intratumoral reduction in [18F]HX4 tumor-to-background ratio (TBR) from 2.53 ± 0.30 to 2.28 ± 0.26 (p = 0.04), as opposed to saline treatment (2.56 ± 0.39 to 3.08 ± 0.39; p = 0.2). The median tumor doubling time (TDT) was 6, 8, 41, and 43 days in the control, metformin, radiotherapy and combination group, respectively (log-rank p < 0.0001), but no metformin-specific therapy effects could be detected. Baseline [18F]HX4 TBR was a negative prognostic biomarker for TDT (hazard ratio, 2.39; p = 0.02). CONCLUSIONS: Metformin decreased [18F]HX4 uptake of Colo205-tumors, but had no additive effect on radiotherapy efficacy. Nevertheless, [18F]HX4 holds promise as a prognostic imaging biomarker.
引用
- De Bruycker S, Vangestel C, Staelens S, et al. Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [18F]HX4 PET imaging study in colorectal cancer xenografts. EJNMMI Res. 2019. PMID: 31375940. doi:10.1186/s13550-019-0543-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。